Table 1:
Values of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), and mean diffusivity 〈D〉 for the entire volume of enhancing tumor pre- and postdexamethasone treatment for the 10 patients participating in this study
| Patient No. | Enhancing Tumor |
|||||||
|---|---|---|---|---|---|---|---|---|
| CBF (mL/100 g/min) |
CBV (mL/100 g) |
MTT (s) |
<D> (×10−6 mm2/s) |
|||||
| Presteroids | Poststeroids | Presteroids | Poststeroids | Presteroids | Poststeroids | Presteroids | Poststeroids | |
| 1 | 45.4 (±18.1) | 42.6 (±20.3) | 4.1 (±2.1) | 2.6 (±1.3) | 3.6 (±0.9) | 2.4 (±0.6) | 1516 (±206) | 1458 (±222) |
| 2 | 41.9 (±13.9) | 49.4 (±19.2) | 5.3 (±1.8) | 5.9 (±2.1) | 5.1 (±0.8) | 4.9 (±1.1) | 1133 (±143) | 1135 (±136) |
| 3 | 56.8 (±34.0) | 58.0 (±32.1) | 6.2 (±4.2) | 5.7 (±3.6) | 4.2 (±1.3) | 3.8 (±1.5) | 1684 (±361) | 1560 (±381) |
| 4 | 29.3 (±8.2) | 29.4 (±9.6) | 2.5 (±0.9) | 2.4 (±0.8) | 3.5 (±0.8) | 3.4 (±0.8) | 1060 (±145) | 951 (±109) |
| 5 | 68.5 (±24.5) | 68.8 (±24.9) | 5.5 (±2.0) | 4.5 (±1.5) | 3.2 (±0.4) | 2.6 (±0.4) | 994 (±96) | 917 (±51) |
| 6 | 61.5 (±20.9) | 70.2 (±31.6) | 5.1 (±1.8) | 6.7 (±3.1) | 3.4 (±0.8) | 3.9 (±0.9) | 1268 (±209) | 1201 (±240) |
| 7 | 56.9 (±25.2) | 62.6 (±28.7) | 4.8 (±2.1) | 4.5 (±1.9) | 3.4 (±0.7) | 2.9 (±0.6) | 1300 (±246) | 1155 (±225) |
| 8 | 71.4 (±35.5) | 51.9 (±27.4) | 6.4 (±3.5) | 3.8 (±2.0) | 3.6 (±1.0) | 3.0 (±0.5) | 1229 (±226) | 1136 (±215) |
| 9 | 49.3 (±21.3) | 52.4 (±21.9) | 4.3 (±1.9) | 5.1 (±2.2) | 3.6 (±0.6) | 3.9 (±1.0) | 1353 (±268) | 1302 (±277) |
| 10 | 49.3 (±22.2) | 46.5 (±22.7) | 4.3 (±2.2) | 4.6 (±2.7) | 3.5 (±1.3) | 4.1 (±1.9) | 914 (±295) | 907 (±258) |
| Mean | 53.0 (±12.7) | 53.2 (±12.4) | 4.8 (±1.1) | 4.6 (±1.4) | 3.7 (±0.6) | 3.5 (±0.8) | 1245 (±236) | 1172 (±221) |
| ε (%); P | 1.2 (±12.8); .95 | −4.6 (±22.9); .49 | −5.6 (±16.0); .28 | −5.8 (±3.8); .001 | ||||
All values are reported as mean (±SD).
The mean volume of enhancing tumor was 24.8 ± 21.4 × 10 mm.